

In the Claims:

1. (Canceled)
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Currently Amended) A method for producing a plurality of crystalline (E) – 4 – [2 – [2 – [N – acetyl – N – (4 – methoxybenzenesulfonyl) amino]phenyl]- ethenyl]pyridine 1-oxide particles with a mean particle diameter of from 1 µm to about 25 µm with particles larger than 50 µm constituting a fraction of not more than 2% of a total number of particles, comprising the step of micronizing the crystalline compound with an open-circuit pulverizing type mill and obtaining a pulverizate in which the crystallinity of the compound is retained.
8. (Currently Amended) The ~~micronizing~~ production method of Claim 7 wherein said open-circuit pulverizing type mill is either a high-speed rotary impact mill or a pneumatic mill.
9. (Canceled)
10. (Canceled)
11. (Withdrawn) A chemical composition comprising a plurality of crystalline (E) – 4 – [2 – [2 – [N – acetyl – N – (4 – methoxybenzenesulfonyl)amino]phenyl]ethenyl] – pyridine 1 – oxide

particles with a mean particle diameter of from 1 μm to about 25 μm with particles larger than 50 μm constituting a fraction of not more than 2% of a total number of particles.

12. (Withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of the plurality of crystalline (E) – 4 – [2 – [2 – [N – acetyl – N – (4 – methoxybenzenesulfonyl)amino]phenyl]ethenyl] – pyridine 1 – oxide particles of claim 11 as an active ingredient.

13. (Withdrawn) An anticancer drug comprising a therapeutically effective amount of the plurality of crystalline (E) – 4 – [2 – [2 – [N – acetyl – N – (4 – methoxybenzenesulfonyl)amino]phenyl]ethenyl] – pyridine 1 – oxide particles of claim 11 as an active ingredient.